1. Home
  2. MDIA vs NYXH Comparison

MDIA vs NYXH Comparison

Compare MDIA & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mediaco Holding Inc.

MDIA

Mediaco Holding Inc.

SELL

Current Price

$0.96

Market Cap

90.7M

ML Signal

SELL

Logo Nyxoah SA

NYXH

Nyxoah SA

SELL

Current Price

$0.82

Market Cap

91.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MDIA
NYXH
Founded
2019
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Broadcasting
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.7M
91.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MDIA
NYXH
Price
$0.96
$0.82
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $2.80
AVG Volume (30 Days)
9.1K
★ 202.5K
Earning Date
11-16-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $133,336,000.00
N/A
Revenue This Year
N/A
$234.49
Revenue Next Year
N/A
$98.07
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 39.52
N/A
52 Week Low
$0.54
$0.80
52 Week High
$1.64
$5.39

Technical Indicators

Market Signals
Indicator
MDIA
NYXH
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
MDIA
NYXH

About MDIA Mediaco Holding Inc.

MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: